Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05550961
Recruiting Observational

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

NCT05550961 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Observational
Started
2022-10-01
Last updated
2023-10-23

Condition(s) studied

NSCLCCancerLung CancerAdenocarcinoma of LungSquamous Cell Lung Cancer

Study summary

APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a "virtual" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo "unity is strength".

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses; 2. Patients must be ≥18 years of age at the time of signing the informed consent; 3. Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies). Exclusion Criteria: 1. Patients who are or will be taking other unapproved antineoplastic therapies concurrently are not eligible. 2. Patients who have not received an oncological systemic innovative therapy at any setting 3. Patients received only local treatments (e.g., only surgery, or only radiotherapy) 4. Patients who received only standard chemotherapy are excluded. 5. Patients who received treatment therapies before 2010 are excluded.

Primary outcome measure(s)

  • Response Rate — About 8 weeks (first radiological evaluation)
    Prediction of response to innovative therapies in NSCLC patients
  • Progression-Free Survival — From data of enrollment until the date of first documented progression or date of death from any cause, whichever come first, assessed up to 120 months
    Prediction of Progression-Free Survival in NSCLC patients treated with innovative therapies
  • Overall Survival — From data of enrollment until the date of death from any cause, assessed up to 120 months
    Prediction of Overall Survival in NSCLC patients treated with innovative therapies

Trial sites (1)

FacilityCityRegionStatus
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy Recruiting

More Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials in Italy

DianaWeb: Before and After Study Online Based Participatory Research on Breast Cancer Women Recruiting
REtroperitoneal SArcoma Registry: an International Prospective Initiative Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN) Recruiting
A Composite Assay for HER2-positive Early-stage Breast Cancer Management Recruiting
Non-invasive Detection of Breast Cancer by Breath Analysis Active, not recruiting

Other trials for the same condition

Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies Recruiting
Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients Recruiting
Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia Recruiting
The SUNRISE Project is Dedicated to Enhancing Primary Cancer Prevention Among Adolescents in Europe by Leveraging Innovative Digital Tools and Methodologies. SmartCoach, Developed by Swiss Research Institute for Public Health and Addiction (ISGF), is a Mobile Phone-based Life-skills Training Program Starting soon
Met Non Small Cell Cancer Registry (MOMENT) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05550961 on ClinicalTrials.gov ↗ ← All trials in Italy